Epoprostenol Sodium

15 Jul 2025 11:05Regulatory Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive topline results from its Phase I trial of CS014, a novel HDAC inhibitor in development for idiopathic pulmonary fibrosis (IPF). The trial confirms a favorable safety and tolerability profile, and data support further clinical evaluation. Based on the findings, preparations are underway to initiate a Phase II trial. “We are very pleased with the outcome of this study and the excellent collaboration with the CRO CTC. CS014 was well-tolerated and showed favorable safety in healthy volunteers. Notably, CS014 was safe and well tolerated at exposure levels that are expected to be sufficient to impact pathological pulmonary vascular remodeling and reduction of fibrosis — key drivers in several rare cardiovascular and pulmonary diseases. These findings position CS014 as a promising candidate in IPF and other rare diseases involving vascular remodeling and fibrosis,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. The Phase I trial evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The trial was conducted in two parts: part one explored safety, tolerability and PK of single ascending oral doses (SAD) of CS014; part two explored safety, tolerability, PK, and PD following multiple ascending doses (MAD) of CS014, dosed for seven days. In total, 48 subjects were included in the trial, 30 in the SAD and 18 in the MAD part. The trial was conducted by CTC in Uppsala, Sweden. Summary of the topline results from the Phase I trial: CS014 demonstrated favorable safety and tolerability in healthy volunteers. All 48 healthy volunteers completed the study; no early withdrawals or deaths were reported. No serious adverse events (SAEs) occurred. All treatment-related adverse events (AEs) reported were mild, transient, and fully recovered. CS014 achieved levels in the blood stream at and above those projected, based on non-clinical data, to be required for achieving maximal effects on reversal of pulmonary vascular remodeling and fibrosis. These findings, combined with non-clinical data demonstrating a favorable impact on plexiform lesions in the Sugen/Hypoxia rat model, offer insights that support dose selection and support advancement into Phase II development. “CS014 is a novel HDAC inhibitor with a unique mechanism of action through epigenetic modulation that could represent a differentiated treatment approach for IPF. These positive Phase I results, combined with strong non-clinical data, give us confidence as we advance into Phase II clinical development. CS014 is a cornerstone of our broader HDAC inhibitor portfolio, which we believe holds significant disease-modifying potential across a range of rare cardiovascular and pulmonary diseases. We are excited to continue pioneering treatments to improve the lives of patients in these diseases with high unmet medical needs,” said Sten R. Sörensen, CEO at Cereno Scientific. The company is advancing plans to prepare for a Phase II trial initiation in H1 2026. Full results from the Phase I trial will be submitted for publication in a peer-reviewed scientific journal. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13:05 CET on July 15, 2025. About CS014 CS014 is a proprietary new chemical entity and a HDAC inhibitor. Being an epigenetic modulator, with a multimodal mechanism of action, CS014 has the potential to target the underlying pathophysiology of several rare cardiovascular and pulmonary diseases with high unmet medical needs. The initial target is idiopathic pulmonary fibrosis (IPF). In non-clinical studies, CS014 has demonstrated strong effects on vascular remodeling and fibrosis, suggesting disease-modifying potential. The findings from the Phase I trial will inform the next steps in advancing CS014 as a potential new treatment for patients with severe, progressive diseases that currently lack effective therapies. Preparations and studies are underway to support the transition to a Phase II trial of CS014. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company has signed an agreement with a top-tier global contract research organization (CRO) relating to the Phase IIb trial of CS1. The selection of a CRO is an important step in the clinical development for CS1 and marks a significant milestone toward the initiation of the Phase IIb trial. CS1 has the potential to become an effective disease-modifying treatment to enhance and extend life for patients with pulmonary arterial hypertension (PAH). “We are excited to have selected this reputable CRO as our partner for the Phase IIb trial of CS1. Partnering with a CRO that combines deep expertise in the disease area with a well-established network of seasoned investigators is essential to the successful execution of clinical trials. This CRO has a proven track record in PAH trials providing access to both highly experienced clinical teams and a broad, well-characterized patient population. Their extensive experience and robust infrastructure are important capacities as we advance our lead candidate CS1’s clinical program in PAH,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. “I am very pleased that our team at Cereno has completed an extensive procurement process leading up to our selection of a CRO for our lead candidate CS1 and its next clinical Phase IIb program in the rare disease PAH. This top-tier global CRO has a superior reputation that precedes them in the industry as well as in the scientific community, which makes them an excellent partner choice for Cereno Scientific as we continue to pursue our pioneering effort to bring epigenetic modulation through HDAC inhibition to patients affected by the devastating disease PAH,” said Sten R. Sörensen, CEO at Cereno Scientific. The Phase IIb trial of CS1 is planned as a global, multi-center, placebo-controlled trial designed to further evaluate the encouraging efficacy signals observed in the Phase IIa trial, including reverse vascular remodeling and improvement of right heart function. In May 2025, the U.S. FDA provided an endorsement of the plans for the Phase IIb trial through a Type C meeting. Preparations for an IND submission are underway, with trial initiation targeted for H1 2026, pending regulatory approvals. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 About CS1 Drug candidate CS1 is currently in Phase II development, being advanced as a first-in-class treat­ment for the rare disease pulmonary arterial hypertension (PAH). CS1 is a histone deacetylase inhibitor (HDACi) that works through epigenetic modulation, uniquely targeting the underlying mechanisms driving disease progression in PAH. Drug candidate CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging signals of reverse vascular remodelling as observed in a Phase IIa trial in patients with the rare disease pulmonary arterial hypertension (PAH). The aim for CS1 is to offer an effective disease-modifying treatment with the ability to enhance quality of life and extend life for PAH patients. Unlike standard therapy that mainly alleviates symptoms, CS1 represents a novel therapeutic approach by targeting the root mechanisms of PAH. Specifically, CS1 aims to reverse the pathological vascular remodeling of the small pulmonary arteries. A successful Phase IIa trial was concluded in 2024. Insights into the long-term use of CS1 are being gathered in an expanded access program with 10 patients from the Phase IIa trial. The next clinical development step of CS1 is a larger, placebo-controlled Phase IIb trial that is expected to be initiated in H1 2026. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share